Memphasys Limited (ASX: MEM) has initiated activities in Brazil, marking a significant step towards entering this key market. This expansion, led by renowned Brazilian andrologist Prof. Jorge Hallak, could extend to other Latin American countries within his scientific influence. Memphasys has partnered with Laboratorio Androscience, a prominent Brazilian IVF clinic, to conduct clinical utility testing of the Felix System.
Under a Non-Disclosure Agreement, the facility has commenced a three-month evaluation involving a Felix console and 20 cartridges. This trial will compare Felix against existing sperm preparation methods and include clinician training. Discussions on a potential licensing agreement for the Brazilian market will follow if successful. Androscience and related stakeholders have also expressed interest in investing in Memphasys to facilitate its market entry. Brazil’s IVF market, projected to reach US$ 413.6 million by 2032, presents a substantial opportunity. Key scientific presentations in 2025 will further support awareness and clinician engagement.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 20, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
